Literature DB >> 25704963

Immune profile modulation of blood and mucosal eosinophils in nasal polyposis with concomitant asthma.

Geoffrey Mortuaire1, Isabelle Gengler2, Claire Vandenhende-Szymanski2, Marie Delbeke3, Solène Gatault3, Dominique Chevalier4, Lionel Prin5, Monique Capron3.   

Abstract

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is frequently associated with asthma. Mucosal eosinophil (EO) infiltrate has been found to correlate with asthma and disease severity but not necessarily in every patient. Other multifactorial immune processes are required to determine disease endotypes and response to treatment.
OBJECTIVE: To evaluate EO immunomodulation for migration and survival in accordance with inflammatory protein profiles and asthmatic status in CRSwNP.
METHODS: Ninety-three patients (47 with asthma) with CRSwNP were included. Each patient was staged clinically according to symptom severity and polyp size. Nasal secretions were collected to establish a cytokine profile. The EOs were purified from blood samples and nasal polyps to delineate specific immunophenotypes by flow cytometry and determine in vitro EO survival in relation to asthmatic status.
RESULTS: The CRSwNP in patients with asthma was characterized by eosinophilia and a high level of interleukin (IL)-5 in nasal secretions. Although EOs exhibited activation profiles after mucosal migration, there was relative down-expression of IL-5 receptor-α (IL-5Rα) on nasal EOs in patients with asthma. The EO culture with IL-5 and IL-9 showed an antiapoptotic effect in patients with asthma through IL-5Rα modulation.
CONCLUSION: Mucosal eosinophilia seems to be induced by EO nasal trapping through modulation of adhesion receptors. In patients with asthma, EO involvement is enhanced by the antiapoptotic synergistic action of T-helper cell type 2 cytokines on IL-5Rα expression. This study shows for the first time that IL-9 is involved in EO homeostasis in CRSwNP and could explain the low benefit of anti-IL-5 therapy for some patients with asthma and nasal polyposis.
Copyright © 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25704963     DOI: 10.1016/j.anai.2015.01.012

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  4 in total

Review 1.  Eosinophils in the Field of Nasal Polyposis: Towards a Better Understanding of Biologic Therapies.

Authors:  Thibault Vanderhaegen; Isabelle Gengler; Arnaud Dendooven; Cecile Chenivesse; Guillaume Lefèvre; Geoffrey Mortuaire
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-26       Impact factor: 8.667

2.  Impact of chronic rhinosinusitis on severe asthma patients.

Authors:  Ta-Jen Lee; Chia-Hsiang Fu; Chun-Hua Wang; Chi-Che Huang; Chien-Chia Huang; Po-Hung Chang; Yi-Wei Chen; Chia-Chen Wu; Ching-Lung Wu; Han-Pin Kuo
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

Review 3.  Cytokine Signature and Involvement in Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Florent Carsuzaa; Émilie Béquignon; Xavier Dufour; Guillaume de Bonnecaze; Jean-Claude Lecron; Laure Favot
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

4.  Eosinophil-related markers and total immunoglobulin E as a predictive marker for antibiotic response in chronic rhinosinusitis.

Authors:  Youn Ho Shin; Hwan Soo Kim; Eu Kyoung Lee; Young Joo Kim; Hyun-Seung Lee; Pil-Sang Jang; Young-Hoon Kim; Yoon Hong Chun; Jong-Seo Yoon; Hyun Hee Kim; Young-Yull Koh; Jin Tack Kim
Journal:  Ann Saudi Med       Date:  2015 Jul-Aug       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.